-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 7, Renfu Pharmaceutical issued an announcement stating that its subsidiary Yichang Renfu Pharmaceutical's nalbuphine hydrochloride injection and midazolam injection were approved as supplementary applications.
Nalbuphine Hydrochloride Injection
Nalbuphine Hydrochloride InjectionThe announcement shows that nalbuphine hydrochloride injection is widely used to relieve moderate to severe pain, and can also be used as anesthesia induction during compound anesthesia.
According to the website of the State Drug Administration, only Yichang Renfu has obtained the production approval for nalbuphine hydrochloride injection in China.
Midazolam Injection
Midazolam InjectionThe announcement shows that midazolam injection is mainly used for preoperative sedation/anxiety/amnesia; diagnosis, treatment, endoscopic surgery; induction and maintenance of general anesthesia; sedation in patients with tracheal intubation, mechanical ventilation and critical care .
According to the website of the State Drug Administration, a total of 4 domestic companies hold production approvals for midazolam injection.